Deals
Having secured deals with AstraZeneca and Novartis, Niowave is constructing a second facility to meet rising demand for actinium-225, which can be used to develop next-generation radiopharmaceuticals.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Reportedly, Madrigal Pharmaceuticals is considering a sale. After receiving interest from other big drug companies, the nine-employee company is evaluating its options.
Alexion Pharmaceuticals is forging a partnership with Complement Pharma to co-develop a C6 complement inhibitor.
Three clinical-stage biotechnology companies announced initial public offerings (IPOs) today. Here’s a summary.
Unity Biotechnology has raised $222 million in venture capital, raised $85 million in an initial public offering (IPO) in May, and has a value of $700 million. All without having a product to sell.
Tricida, a late-stage biotech company developing therapies for conditions associated with chronic kidney disease (CKD), filed late Monday with the Securities and Exchange Commission to raise up to $150 million in an initial public offering.
Eight biotechs launched initial public offerings (IPO) in May, April wasn’t as hot a month, with only two. But June is off to a good start with two.
U.S. Justice Department gave the merger the go-ahead after Monsanto agreed to sell approximately $9 billion in assets.
On April 5, San Francisco’s Eidos Therapeutics closed on a Series B financing round worth $64 million. Now the company has filed with the U.S. Securities and Exchange Commission (SEC) to raise $115 million through an initial public offering (IPO).
It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
Weeks after securing $52 million in a Series C financing, Magenta Therapeutics is eying the raising of $100 million in an initial public offering two years after it was launched by Third Rock Ventures and Atlas Venture with $48.5 million in Series A financing.